Overview

The marketing authorisation for Comfortis has been withdrawn at the request of the marketing authorisation holder

български (BG) (236.57 KB - PDF)

View

español (ES) (187.74 KB - PDF)

View

čeština (CS) (226.05 KB - PDF)

View

dansk (DA) (161.59 KB - PDF)

View

Deutsch (DE) (171.6 KB - PDF)

View

eesti keel (ET) (155.77 KB - PDF)

View

ελληνικά (EL) (264.18 KB - PDF)

View

français (FR) (189.24 KB - PDF)

View

hrvatski (HR) (198.87 KB - PDF)

View

italiano (IT) (161.61 KB - PDF)

View

latviešu valoda (LV) (225.08 KB - PDF)

View

lietuvių kalba (LT) (224.56 KB - PDF)

View

magyar (HU) (217.9 KB - PDF)

View

Malti (MT) (216.58 KB - PDF)

View

Nederlands (NL) (191.07 KB - PDF)

View

polski (PL) (205.46 KB - PDF)

View

português (PT) (165.42 KB - PDF)

View

română (RO) (234.04 KB - PDF)

View

slovenčina (SK) (203.46 KB - PDF)

View

slovenščina (SL) (219.22 KB - PDF)

View

Suomi (FI) (179.48 KB - PDF)

View

svenska (SV) (185.78 KB - PDF)

View

Product information

български (BG) (1 MB - PDF)

View

español (ES) (788.73 KB - PDF)

View

čeština (CS) (931.05 KB - PDF)

View

dansk (DA) (761.7 KB - PDF)

View

Deutsch (DE) (837.99 KB - PDF)

View

eesti keel (ET) (986.97 KB - PDF)

View

ελληνικά (EL) (1.1 MB - PDF)

View

français (FR) (813.94 KB - PDF)

View

hrvatski (HR) (961.72 KB - PDF)

View

íslenska (IS) (733.62 KB - PDF)

View

italiano (IT) (835.06 KB - PDF)

View

latviešu valoda (LV) (1.1 MB - PDF)

View

lietuvių kalba (LT) (1.05 MB - PDF)

View

magyar (HU) (924.98 KB - PDF)

View

Malti (MT) (1.01 MB - PDF)

View

Nederlands (NL) (803.63 KB - PDF)

View

norsk (NO) (762.11 KB - PDF)

View

polski (PL) (993.24 KB - PDF)

View

português (PT) (802.47 KB - PDF)

View

română (RO) (969.27 KB - PDF)

View

slovenčina (SK) (943.68 KB - PDF)

View

slovenščina (SL) (925.44 KB - PDF)

View

Suomi (FI) (789.17 KB - PDF)

View

svenska (SV) (753.4 KB - PDF)

View

Latest procedure affecting product information: IB/0025/G

10/09/2021

български (BG) (351.84 KB - PDF)

View

español (ES) (294.94 KB - PDF)

View

čeština (CS) (261.47 KB - PDF)

View

dansk (DA) (280.02 KB - PDF)

View

Deutsch (DE) (288.43 KB - PDF)

View

eesti keel (ET) (287.9 KB - PDF)

View

ελληνικά (EL) (326.3 KB - PDF)

View

français (FR) (295.94 KB - PDF)

View

hrvatski (HR) (329.99 KB - PDF)

View

íslenska (IS) (296.28 KB - PDF)

View

italiano (IT) (291.52 KB - PDF)

View

latviešu valoda (LV) (321.16 KB - PDF)

View

lietuvių kalba (LT) (267.62 KB - PDF)

View

magyar (HU) (305.68 KB - PDF)

View

Malti (MT) (310.01 KB - PDF)

View

Nederlands (NL) (288.83 KB - PDF)

View

norsk (NO) (282.34 KB - PDF)

View

polski (PL) (310.43 KB - PDF)

View

português (PT) (284.42 KB - PDF)

View

română (RO) (294.1 KB - PDF)

View

slovenčina (SK) (310.17 KB - PDF)

View

slovenščina (SL) (345.29 KB - PDF)

View

Suomi (FI) (287.08 KB - PDF)

View

svenska (SV) (286.33 KB - PDF)

View

Product details

Name of medicine
Comfortis
Active substance
spinosad
International non-proprietary name (INN) or common name
spinosad
Species
  • Dogs
  • Cats
Anatomical therapeutic chemical veterinary (ATCvet) code
QP53BX03

Pharmacotherapeutic group

Other ectoparasiticides for systemic use

Therapeutic indication

Treatment and prevention of flea infestations (Ctenocephalides felis).

The preventive effect against re-infestations is a result of the adulticidal activity and the reduction in egg production and persists for up to 4 weeks after a single administration of the product.

The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).

Authorisation details

EMA product number
EMEA/V/C/002233
Marketing authorisation holder
Elanco GmbH

Heinz-Lohmann-Str. 4
27472 Cuxhaven
Germany

Opinion adopted
08/12/2010
Marketing authorisation issued
11/02/2011
Revision
12

Assessment history

News on Comfortis

Topics

This page was last updated on

How useful do you find this page?